Two-Stage Exchange Using a Total Femur Spacer in the Management of Periprosthetic Joint Infection – Spacer Complications and Implant Survivorships

• Published in: The Journal of arthroplasty 2023-10, Vol.38 (10), p.2171-2176
• Main Authors: Theil, Christoph, Moellenbeck, Burkhard, Puetzler, Jan, Klingebiel, Sebastian, Schwarze, Jan, Gosheger, Georg
• Format: Article
• Language: English
• Subjects: megaprosthesis; periprosthetic joint infection; revision arthroplasty; THA; TKA
• ISSN: 0883-5403; 1532-8406
• DOI: 10.1016/j.arth.2023.04.057

Chronic periprosthetic joint infection after revision hip and knee arthroplasties can lead to subsequent massive femoral bone loss. In these cases, resection of the residual femur and placement of an antibiotic total femoral spacer can be an option to salvage the limb. This is a single-center retrospective analysis of 32 patients (median age 67 years; range 15-93; 18 women) who underwent placement of a total femur spacer for chronic periprosthetic joint infection with massive femoral bone loss between 2010 and 2019 as part of a planned two-stage exchange. The median follow-up period amounted to 46 months (range, 1-149). Implant and limb survival were analyzed using Kaplan-Meier survival estimates. Potential risk factors for failure were analyzed. There were 34% (11 of 32) of patients having a spacer-associated complication, and 25% underwent revision for this reason. After the first stage, 92% were considered infection-free. There were 84% of patients who underwent second-stage reimplantation of a total femoral arthroplasty using a modular megaprosthetic implant. Infection-free implant survival was 85% after 2 years and 53% after 5 years. There were 44% of patients who underwent amputation after a median time of 40 months (range, 2-110). Most commonly, coagulase-negative staphylococci were cultured at first-stage surgery, while polymicrobial growth was most common at reinfection. Total femur spacers can lead to infection control in over 90% of cases with a reasonable complication rate for the spacer itself. However, the reinfection and subsequent amputation rate after second-stage megaprosthetic total femoral arthroplasty is around 50%.